Business context and reporting period
Nasus Pharma Ltd. furnished this Form 6-K for October 2026. It reports the results of the company’s Annual and Special General Meeting held on October 8, 2026.
Key financial metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Meeting results and material changes
A quorum was present. Shareholders approved all agenda items by the applicable required majority except Proposal No. 4. The filing does not identify Proposal No. 4’s subject or provide vote counts; it refers readers to the meeting notice and proxy statement furnished on September 4, 2026.
Other disclosures and considerations
The report is incorporated by reference into the company’s Form F-3 registration statement (File No. 333-298693) and Form S-8 registration statement (File No. 333-296252), subject to subsequent filings or reports. The filing provides no business outlook, management commentary, risk updates, or contingencies.
Facts to verify
- What Proposal No. 4 covered and why it was not approved.
- Vote counts and outcomes for each agenda item in the meeting materials.
- Whether the meeting results affect the company’s securities or registration statements.